MLYS vs. VRNA, RVMD, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVL
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs. Its Competitors
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
Verona Pharma PLC American Depositary Share has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Verona Pharma PLC American Depositary Share has higher revenue and earnings than Mineralys Therapeutics. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Verona Pharma PLC American Depositary Share had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Verona Pharma PLC American Depositary Share and 4 mentions for Mineralys Therapeutics. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.10 beat Mineralys Therapeutics' score of 0.50 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media.
Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 1.95%. Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential upside of 3.59%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Verona Pharma PLC American Depositary Share.
Mineralys Therapeutics has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Mineralys Therapeutics' return on equity.
Summary
Verona Pharma PLC American Depositary Share beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 10/13/2025 by MarketBeat.com Staff